KDNY Chinook Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KDNY

Price (delayed)

$22.23

Market cap

$1.46B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.92

Enterprise value

$1.39B

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined ...

Highlights
Chinook Therapeutics's debt has decreased by 10% YoY and by 2.8% QoQ
Chinook Therapeutics's gross profit has plunged by 89% from the previous quarter and by 88% YoY
The revenue has dropped by 89% since the previous quarter and by 88% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http:///www.chinooktx.com
Peers: OVID

Key stats

What are the main financial stats of KDNY
Market
Shares outstanding
65.85M
Market cap
$1.46B
Enterprise value
$1.39B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.22
Price to sales (P/S)
233.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
226.12
Earnings
Revenue
$6.13M
EBIT
-$183.52M
EBITDA
-$172.15M
Free cash flow
-$119.13M
Per share
EPS
-$2.92
Free cash flow per share
-$1.85
Book value per share
$6.91
Revenue per share
$0.1
TBVPS
$8.54
Balance sheet
Total assets
$574.08M
Total liabilities
$132.14M
Debt
$39.44M
Equity
$441.94M
Working capital
$334.76M
Liquidity
Debt to equity
0.09
Current ratio
7.59
Quick ratio
7.5
Net debt/EBITDA
0.45
Margins
EBITDA margin
-2,809.2%
Gross margin
100%
Net margin
-3,065.7%
Operating margin
-3,020.3%
Efficiency
Return on assets
-32.7%
Return on equity
-40.6%
Return on invested capital
-43.2%
Return on capital employed
-35.1%
Return on sales
-2,994.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KDNY stock price

How has the Chinook Therapeutics stock price performed over time
Intraday
-0.13%
1 week
0.05%
1 month
2.4%
1 year
41.59%
YTD
-15.15%
QTD
-15.15%

Financial performance

How have Chinook Therapeutics's revenue and profit performed over time
Revenue
$6.13M
Gross profit
$6.13M
Operating income
-$185.08M
Net income
-$187.87M
Gross margin
100%
Net margin
-3,065.7%
Chinook Therapeutics's gross profit has plunged by 89% from the previous quarter and by 88% YoY
The revenue has dropped by 89% since the previous quarter and by 88% year-on-year
Chinook Therapeutics's operating income has plunged by 87% YoY and by 64% from the previous quarter
KDNY's net income has dropped by 83% year-on-year and by 60% since the previous quarter

Growth

What is Chinook Therapeutics's growth rate over time

Valuation

What is Chinook Therapeutics stock price valuation
P/E
N/A
P/B
3.22
P/S
233.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
226.12
Chinook Therapeutics's EPS has plunged by 72% from the previous quarter and by 29% YoY
KDNY's price to book (P/B) is 24% more than its last 4 quarters average of 2.6 and 19% more than its 5-year quarterly average of 2.7
The equity has contracted by 7% from the previous quarter and by 2.6% YoY
KDNY's P/S is 178% above its last 4 quarters average of 84.1 and 63% above its 5-year quarterly average of 143.5
The revenue has dropped by 89% since the previous quarter and by 88% year-on-year

Efficiency

How efficient is Chinook Therapeutics business performance
KDNY's return on equity has dropped by 60% since the previous quarter and by 30% year-on-year
The return on assets has dropped by 59% since the previous quarter and by 39% year-on-year
KDNY's ROIC has plunged by 54% from the previous quarter and by 12% YoY

Dividends

What is KDNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KDNY.

Financial health

How did Chinook Therapeutics financials performed over time
The total liabilities has grown by 20% YoY and by 14% from the previous quarter
The company's quick ratio fell by 11% QoQ
Chinook Therapeutics's debt is 91% lower than its equity
Chinook Therapeutics's debt has decreased by 10% YoY and by 2.8% QoQ
The debt to equity has declined by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.